Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21233179 | 0.83 | TSHR (0.44) | ALDH1A1SMN1; SMN2NPC1TP53TSHR | |
| SCHEMBL31597376 | 0.72 | KMT2A (0.40) | — | |
| SCHEMBL31597336 | 0.71 | CYP2C9 (0.36) | TSHR | |
| SCHEMBL26051626 | 0.70 | ALDH1A1 (0.34) | HDAC6ALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL21241221 | 0.69 | BRD4 (0.36) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4APOBEC3G | |
| SCHEMBL26206453 | 0.66 | ALDH1A1 (0.43) | HDAC6ALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL21233180 | 0.66 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4APOBEC3G | |
| SCHEMBL26847652 | 0.66 | ACHE (0.40) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4APOBEC3G | |
| SCHEMBL31596016 | 0.65 | BAZ2B (0.32) | HDAC6ALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL21233123 | 0.63 | ALDH1A1 (0.34) | HDAC6ALDH1A1SMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | PAH, BCKDK, PKM | HDAC6 2873/4885ALDH1A1 634/4885SMN1; SMN2 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.